Intervention

Docetaxel injection

ClinicalTrials.gov intervention label

Clinical trials9

Recruiting4

Common conditions9

Lead sponsors shown8

Clinical trials

9 shown

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureNCT06300177 · 2024-03-28

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsNCT06079983 · 2023-12-01

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）NCT06107673 · 2023-09-30

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT05942001 · 2023-08-03

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerNCT07196774 · 2025-10-23

ACTIVE_NOT_RECRUITING

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC StageNCT05627752 · 2024-06-01

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody TreatmentNCT05661240 · 2022-12-20

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and ChemotherapyNCT04878107 · 2022-03-15

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate CancerNCT04869371 · 2018-12-12

Common conditions

Breast Cancer2 Advanced Prostate Cancer1 Castrate Resistant Prostate Cancer1 Early-stage or Locally Advanced HER2-positive Breast Cancer1 Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel1 Non Small Cell Lung Cancer1 Non-Small Cell Lung Cancer1 Non-small Cell Lung Cancer (NSCLC)1 Prostate Cancer1

Leading sponsors

Jiangsu HengRui Medicine Co., Ltd.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1 Hebei Medical University Fourth Hospital1 Hongqian Guo1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd1 Jiangsu Healthy Life Innovation Medical Technology Co., Ltd1 Wuhan University1 Zhongnan Hospital1

Trial status mix

RECRUITING4

UNKNOWN4

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE25

PHASE35

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.